Receptor targeting of adeno-associated virus vectors

Gene Therapy

Volumn 10, Issue 14, 2003, Pages 1142-1151

  Buning H ^a   Ried, M U ^a   Perabo, L ^a   Gerner, F M ^a   Huttner, N A ^a   Enssle, J ^a   Hallek, M ^a,b,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Adeno associated virus; Bispecific antibody; Capsid modification; Cell specific vectors; Ligand insertion; Receptor targeting

Indexed keywords

BISPECIFIC ANTIBODY; PARVOVIRUS VECTOR; VIRUS PROTEIN; VIRUS VECTOR;

CELL MEMBRANE; CELL SPECIFICITY; DNA MODIFICATION; GENE TARGETING; GENE TRANSFER; GENETIC TRANSDUCTION; HOST RANGE; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SAFETY; TISSUE SPECIFICITY; VIRAL GENE THERAPY; VIRUS CAPSID; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INFECTION; VIRUS TITRATION; WILD TYPE;

ANIMALS; ANTIBODIES; CAPSID PROTEINS; DEPENDOVIRUS; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; GENOME, VIRAL; HUMANS; LIGANDS; RECEPTORS, CELL SURFACE; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS 2; DNA VIRUSES; INSERTION SEQUENCES; PARVOVIRUS;

EID: 0041808929     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301976     Document Type: Review

References (86)

1. Blacklow NR et al. Epidemiology of adenovirus-associated virus infection in a nursery population. Am J Epidemiol 1968; 88: 368-378.
2. Blacklow NR et al. A seroepidemiologic study of adenovirus-associated virus infection in infants and children. Am J Epidemiol 1971; 94: 359-366.
3. Blacklow NR. Adeno-associated virus of humans. In: Pettison J (eds.) Parvovirus Hum Dis 1988; 165-174.
4. Hermonat PL. The adeno-associated virus Rep78 gene inhibits cellular transformation induced by bovine papillomavirus. Virology 1989; 172: 253-261.
5. Mayor HD, Houlditch GS, Mumford DM. Influence of adeno-associated satellite virus on adenovirus-induced tumours in hamsters. Nat New Biol 1973; 241: 44-46.
6. Khleif SN, Myers T, Carter BJ, Trempe JP. Inhibition of cellular transformation by the adeno-associated virus rep gene. Virology 1991; 181: 738-741.
7. Carter PJ, Samulski RJ. Adeno-associated viral vectors as gene delivery vehicles. Int J Mol Med 2000; 6: 17-27.
8. Kotin RM et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990; 87: 2211-2215.
9. Samulski RJ et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991; 10: 3941-3950.
10. Monahan PE, Samulski RJ. Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 2000; 6: 433-440.
11. Tal J. Adeno-associated virus-based vectors in gene therapy. J Biomed Sci 2000; 7: 279-291.
12. Rivadeneira ED et al. Sites of recombinant adeno-associated virus integration. Int J Oncol 1998; 12: 805-810.
13. Balague C, Kalla M, Zhang WW. Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. J Virol 1997; 71: 3299-3306.
14. Rabinowitz JE, Samulski RJ. Building a better vector: the manipulation of AAV virions. Virology 2000; 278: 301-308.
15. Hermonat PL et al. Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J Virol 1984; 51: 329-339.
16. Smuda JW, Carter BJ. Adeno-associated viruses having nonsense mutations in the capsid genes: growth in mammalian cells containing an inducible amber suppressor. Virology 1991; 184: 310-318.
17. Tratschin JD, Miller IL, Carter BJ. Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function. J Virol 1984; 51: 611-619.
18. Wistuba A, Weger S, Kern A, Kleinschmidt JA. Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins. J Virol 1995; 69: 5311-5319.
19. Wistuba A et al. Subcellular compartmentalization of adeno-associated virus type 2 assembly. J Virol 1997; 71: 1341-1352.
20. Hoque M et al. Nuclear transport of the major capsid protein is essential for adeno-associated virus capsid formation. J Virol 1999; 73: 7912-7915.
21. Ruffing M, Zentgraf H, Kleinschmidt JA. Assembly of viruslike particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells. J Virol 1992; 66: 6922-6930.
22. Dubielzig R et al. Adeno-associated virus type 2 protein interactions: formation of pre-encapsidation complexes. J Virol 1999; 73: 8989-8998.
23. Summerford C, Bartlett JS, Samulski RJ. Alpha Vbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 1999; 5: 78-82.
24. Hermens WT et al. Purification of recombinant adeno-associated virus by iodixanol gradient ultracentrifugation allows rapid and reproducible preparation of vector stocks for gene transfer in the nervous system. Hum Gene Ther 1999; 10: 1885-1891.
25. Girod A et al. Genetic capsid modifications allow efficient re-targeting of adeno- associated virus type 2. Nat Med 1999; 5: 1052-1056.
26. Grimm D, Kleinschmidt JA. Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use. Hum Gene Ther 1999; 10: 2445-2450.
27. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
28. Ferrari FK, Xiao X, McCarty D, Samulski RJ. New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. Nat Med 1997; 3: 1295-1297.
29. Chiorini JA et al. High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors. Hum Gene Ther 1995; 6: 1531-1541.
30. Summerford C, Samulski RJ. Viral receptors and vector purification: new approaches for generating clinical-grade reagents. Nat Med 1999; 5: 587-588.
31. Zolotukhin S et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999; 6: 973-985.
32. Xie Q et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 10405-10410.
33. Kronenberg S, Kleinschmidt JA, Bottcher B. Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids. EMBO Rep 2001; 2: 997-1002.
34. Tsao J et al. The three-dimensional structure of canine parvovirus and its functional implications. Science 1991; 251: 1456-1464.
35. Agbandje M et al. Structure determination of feline panleukopenia virus empty particles. Proteins 1993; 16: 155-171.
36. Agbandje-McKenna M et al. Functional implications of the structure of the murine parvovirus, minute virus of mice. Structure 1998; 6: 1369-1381.
37. Agbandje M et al. The structure of human parvovirus B19 at 8 A resolution. Virology 1994; 203: 106-115.
38. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445.
39. Wu P et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 2000; 74: 8635-8647.
40. Rabinowitz JE, Xiao W, Samulski RJ. Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 1999; 265: 274-285.
41. Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol 2000; 74: 2777-2785.
42. Qing K et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 1999; 5: 71-77.
43. Sanlioglu S et al. Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J Virol 2000; 74: 9184-9196.
44. Duan D et al. Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol 1999; 73: 10371-10376.
45. Wang K, Huang S, Kapoor-Munshi A, Nemerow G. Adenovirus internalization and infection require dynamin. J Virol 1998; 72: 3455-3458.
46. Marks B et al. GTPase activity of dynamin and resulting conformation change are essential for endocytosis. Nature 2001; 410: 231-235.
47. Sever S, Damke H, Schmid SL. Dynamin:GTP controls the formation of constricted coated pits, the rate limiting step in clathrin-mediated endocytosis. J Cell Biol 2000; 150: 1137-1148.
48. Douar AM, Poulard K, Stockholm D, Danos O. Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol 2001; 75: 1824-1833.
49. Marsh M, Helenius A. Virus entry into animal cells. Adv Virus Res 1989; 36: 107-151.
50. Girod A et al. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol 2002; 83: 973-978.
51. Zadori Z et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev Cell 2001; 1: 291-302.
52. Seisenberger G et al. Real-time single-molecule imaging of the infection pathway of an adeno-associated virus. Science 2001; 294: 1929-1932.
53. Samulski RJ, Berns KI, Tan M, Muzyczka N. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA 1982; 79: 2077-2081.
54. Chiorini JA et al. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol 1997; 71: 6823-6833.
55. Muramatsu S, Mizukami H, Young NS, Brown KE. Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology 1996; 221: 208-217.
56. Rutledge EA, Halbert CL, Russell DW. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol 1998; 72: 309-319.
57. Chiorini JA, Kim F, Yang L, Kotin RM. Cloning and characterization of adeno-associated virus type 5. J Virol 1999; 73: 1309-1319.
58. Hildinger M et al. Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J Virol 2001; 75: 6199-6203.
59. Halbert CL et al. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J Virol 2000; 74: 1524-1532.
60. Kaludov N et al. Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 2001; 75: 6884-6893.
61. Bantel-Schaal U, Delius H, Schmidt R, zur Hausen H. Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses. J Virol 1999; 73: 939-947.
62. Seiler M et al. AAV5 and AAV6 mediate gene transfer to human airway epithelia via different receptors. Mol. Ther. 2002; 5: S40, abstract No. 117.
63. Rabinowitz JE et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76: 791-801.
64. Xiao W et al. Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999; 73: 3994-4003.
65. Handa A et al. Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. J Gen Virol 2000; 81: 2077-2084.
66. Zabner J et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000; 74: 3852-3858.
67. Halbert CL, Allen JM, Miller AD. Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol 2001; 75: 6615-6624.
68. Davidson BL et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 2000; 97: 3428-3432.
69. Cosset FL, Russell SJ. Targeting retrovirus entry. Gene Ther 1996; 3: 946-956.
70. Miller AD. Cell-surface receptors for retroviruses and implications for gene transfer. Proc Natl Acad Sci USA 1996; 93: 11407-11413.
71. Walter W, Stein U. Cell type specific and inducible promotors for vectors in gene therapy as an approach for cell targeting. J Mol Med 1996; 74: 379-392.
72. Grifman M et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 2001; 3: 964-975.
73. Shi W, Arnold GS, Bartlett JS. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther 2001; 12: 1697-1711.
74. Yang Q et al. Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Hum Gene Ther 1998; 9: 1929-1937.
75. Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol 1999; 17: 181-186.
76. Nicklin SA et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 2001; 4: 174-181.
77. Ried MU et al. Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors. J Virol 2002; 76: 4559-4566.
78. Ziady AG et al. Gene transfer into hepatoma cell lines via the serpin enzyme complex receptor. Am J Physiol 1997; 273G: 545-552.
79. Chapman MS, Rossmann MG. Structure, sequence, and function correlations among parvoviruses. Virology 1993; 194: 491-508.
80. Weichert WS et al. Assaying for structural variation in the parvovirus capsid and its role in infection. Virology 1998; 250: 106-117.
81. Aumailley M et al. Identification of the Arg-Gly-Asp sequence in laminin A chain as a latent cell-binding site being exposed in fragment P1. FEBS Lett 1990; 262: 82-86.
82. White JM. Integrins as virus receptors. Curr Biol 1993; 3: 596-599.
83. Grimm D et al. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther 1999; 6: 1322-1330.
84. Ohno K et al. Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat Biotechnol 1997; 15: 763-767.
85. Sinha P, Sengupta J, Ray PK. Functional mimicry of protein A of Staphylococcus aureus by a proteolytically cleaved fragment. Biochem Biophys Res Commun 1999; 260: 111-116.
86. Perabo L et al. In vitro evolution of receptor specific gene vectors: the adeno-associated virus display, submitted.